{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:05Z","timestamp":1792068845252,"version":"4.4.0"},"reference-count":25,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["IJMS"],"abstract":"<jats:p>Anti-amyloid monoclonal antibodies have finally achieved their translational breakthrough after many years of unmet expectations. The FDA granted traditional approval to lecanemab in July 2023, and the European Medicines Agency approved it in late 2024 with specific genetic restrictions; meanwhile, donanemab received FDA approval in July 2024 and EMA marketing authorization just one month ago. These agents consistently clear cerebral amyloid and slow clinical decline modestly in early-stage, biomarker-confirmed Alzheimer\u2019s disease (AD). On the other hand, they also create significant safety risks, including amyloid-related imaging abnormalities (ARIA) and substantial operational requirements for health systems that are already under pressure. Therefore, precise risk management based on APOE genotyping and the presence of cerebral amyloid angiopathy and cerebral microbleeds should be performed before therapy is initiated. The near-term agenda should prioritize the following areas of study: (1) biomarker-driven front-end triage (including emerging plasma assays); (2) ARIA-aware care pathways and shared decision making; (3) outcome-based coverage and rational pricing; (4) clinical trials that layer anti-amyloid therapy into combinatorial strategies targeting tau protein, neuroinflammation, and synaptic resilience.<\/jats:p>","DOI":"10.3390\/ijms26199529","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:38:55Z","timestamp":1759246735000},"page":"9529","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Anti-Amyloid Therapies for Alzheimer\u2019s Disease: Progress, Pitfalls, and the Path Ahead"],"prefix":"10.3390","volume":"26","author":[{"given":"Vasileios","family":"Papaliagkas","sequence":"first","affiliation":[{"name":"Laboratory of Neurophysiology and Cognitive Neuroscience, Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, 57001 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"ref_3","unstructured":"European Medicines Agency (2025, August 21). Kisunla. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kisunla."},{"key":"ref_4","unstructured":"Biogen (2025, August 24). Biogen to Realign Resources for Alzheimer\u2019s Disease Franchise Biogen. Biogen., Available online: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-realign-resources-alzheimers-disease-franchise."},{"key":"ref_5","first-page":"e12503","article-title":"Validation of 3- and 5-point severity scales to assess ARIA-E","volume":"15","author":"Bracoud","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: Appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-pa for stroke","volume":"388","author":"Reish","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","unstructured":"Peripheral and Central Nervous System Drugs Advisory Committee (2024, October 07). Donanemab for the Treatment of Patients with Early Symptomatic Alzheimer\u2019s disease: Sponsor Briefing Document, Available online: https:\/\/www.fda.gov\/media\/179167\/download."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/STR.0000000000000480","article-title":"Vascular Neurology Considerations for Antiamyloid Immunotherapy: A Science Advisory From the American Heart Association","volume":"56","author":"Greenberg","year":"2025","journal-title":"Stroke"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_12","unstructured":"(2025, August 21). Biogen. Available online: https:\/\/www.leqembihcp.com\/about-leqembi\/study-2-clarity-ad."},{"key":"ref_13","unstructured":"(2025, August 21). Government U.K. Donanemab Licensed for Early Stages of Alzheimer\u2019s Disease in Adult Patients Who Have One or No Copies of Apolipoprotein E4 Gene, Available online: https:\/\/www.gov.uk\/government\/news\/donanemab-licensed-for-early-stages-of-alzheimers-disease-in-adult-patients-who-have-one-or-no-copies-of-apolipoprotein-e4-gene."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): Radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00415-025-13059-3","article-title":"Patient journey and decision processes for anti-amyloid therapy in Alzheimer\u2019s disease","volume":"272","author":"Mittler","year":"2025","journal-title":"J. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e70038","DOI":"10.1002\/alz.70038","article-title":"Diagnostic accuracy of plasma p-tau217\/A\u03b242 for Alzheimer\u2019s disease in clinical and community cohorts","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_17","first-page":"e75907","article-title":"Aducanumab in Alzheimer\u2019s Disease: A Comparative Study of Its Effects on Dementia and Mild Cognitive Impairment","volume":"16","year":"2024","journal-title":"Cureus"},{"key":"ref_18","unstructured":"(2025, August 21). Centers for Medicare and Medicaid Services, Available online: https:\/\/www.cms.gov\/newsroom\/fact-sheets\/medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment-alzheimers-disease."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yoon, C.H., Groff, C., and Criss, O. (2024). Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer\u2019s Disease. Innov. Pharm, 15.","DOI":"10.24926\/iip.v15i1.5787"},{"key":"ref_20","unstructured":"Eli Lilly (2025, August 21). Lilly\u2019s Kisunla\u2122 (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer\u2019s Disease. Available online: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early."},{"key":"ref_21","unstructured":"ICER (2025, August 21). ICER Publishes Final Evidence Report on Lecanemab for Alzheimer\u2019s Disease. Available online: https:\/\/icer.org\/news-insights\/press-releases\/icer-publishes-final-evidence-report-on-lecanemab-for-alzheimers-disease\/."},{"key":"ref_22","unstructured":"Fujirebio (2025, August 21). Fujirebio Receives Marketing Clearance for Lumipulse\u00ae G pTau 217\/\u03b2-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients with Amyloid Pathology Associated with Alzheimer\u2019s Disease. Available online: https:\/\/www.fujirebio.com\/en-us\/news-events\/fujirebio-receives-marketing-clearance-for-lumipulser-g-ptau-217bamyloid-142-plasma-0."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","article-title":"Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform","volume":"31","author":"Palmqvist","year":"2025","journal-title":"Nat. Med."},{"key":"ref_24","unstructured":"Canadian Agency for Drugs and Technologies in Health (2024). Health System Readiness for Disease-Modifying Therapies for Alzheimer Disease: Health Systems, Canadian Agency for Drugs and Technologies in Health. Report No.: CM0003."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-Related Imaging Abnormalities with Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9529\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:51:08Z","timestamp":1759247468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":25,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26199529"],"URL":"https:\/\/doi.org\/10.3390\/ijms26199529","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}